Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
Pricing regulator closely watching prices of diabetes drug going off patent
Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations
Generic gliptin's market grows at the expense of patented medicines
Once the generic version has more trial data, it's most likely to obliterate its patented counterparts in the future
